Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Elizabeth Bancroft(Royal Marsden NHS Foundation Trust), Apollonia T. Helderman-van den Enden(Maastricht University), Jackie Cook(Sheffield Children's Hospital), Jonathan Hoffman(Birmingham Women's Hospital), Donna McBride(Princess Anne Hospital), Hans F. A. Vasen, Barbara Bulman(Manchester Academic Health Science Centre), Christina G. Selkirk(NorthShore University HealthSystem), Saundra Buys(University of Utah), Gerald W. Verhaegh(Radboud University Nijmegen), Andrew J. Vickers(Memorial Sloan Kettering Cancer Center), Derek J. Rosario(Royal Hallamshire Hospital), William D. Foulkes(McGill University), Louise Taylor(Royal Marsden NHS Foundation Trust), Mariëlle Ruijs(The Netherlands Cancer Institute), Anders Bojesen(Vejle Sygehus), Daniel D. Sjoberg(Memorial Sloan Kettering Cancer Center), Kai‐Ren Ong(Birmingham Women's Hospital), Margreet G.E.M. Ausems(McGill University Health Centre), Melissa Assel(Memorial Sloan Kettering Cancer Center), Janneke Ringelberg(Hereditary Disease Foundation), Jacquelyn Powers(University of Pennsylvania), Lambertus A. Kiemeney(Oslo University Hospital), Manuel R. Teixeira(Universidade do Porto), Jimmy Lam(Flinders Medical Centre), Nassim Taherian(McGill University), Hans Lilja(Lund University), Susan M. Domchek(University of Pennsylvania), Dominika Wokołorczyk(International Hereditary Cancer Center), Ignacio Blanco, Peter J. Hulick(NorthShore University HealthSystem), Elena Castro(Hospital Universitario 12 De Octubre), Kate Drew(Peter MacCallum Cancer Centre), Lovise Mæhle(Oslo University Hospital), D. Gareth Evans(Institute of Cancer Research), Sofia Maia(Instituto Português de Oncologia Francisco Gentil), Christopher S. Foster(Institute of Cancer Research), Anne‐Bine Skytte(Aarhus University Hospital), Cezary Cybulski(International Hereditary Cancer Center), Wendy A. van Zelst-Stams(Radboud University Nijmegen), Rogier A. Oldenburg(Erasmus MC), Jan C. Oosterwijk(University Medical Center Groningen), Gillian Mitchell(Peter MacCallum Cancer Centre), Elizabeth Page(Institute of Cancer Research), Tom Conner(University of Utah), R.G.H.M. Cremers(Radboud University Nijmegen), Mónica Salinas(Institut d'Investigació Biomédica de Bellvitge), Diana Eccles(Princess Anne Hospital), Karol Axcrona(Norwegian Cancer Society)
Cited by 250
Related Papers
Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k